The China Liver Health Promotion Forum, co-organized by the CLH, WHO, CDC and China Medical Tribune, was held on 16 December 2021 in a web-based online format. More than 4000 experts, scholars, and medical workers from relevant academic institutions, public welfare institutions, and grassroots medical and health institutions gathered to conduct thematic discussions and exchanges on the global plan to eliminate viral hepatitis and related disease threats, China's actions, grassroots models, and progress hotspots to implement the spirit of the "Healthy China 2030" Plan Outline, around the theme of the conference of "integration of medicine and prevention to eliminate the threat of hepatitis by 2030". Zhuang Hui, Honorary Chairman of the China Liver Health and academician of Peking University Health Science Center, gave a summary of the conference.
Speech by Academician Zhuang Hui At the meeting, Dr. Chen Zhongdan from the WHO Representative Office in China explained the WHO Global Initiative to Eliminate Viral Hepatitis; researcher Liu Zhongfu, Secretary of the Center for Prevention and Control of HIV/AIDS of the Chinese CDC, explained the Work Plan for the Action to Eliminate the Public Health Hazards of Hepatitis C (2021-2030) issued by nine ministries and commissions, including the National Health Commission; Prof. Wang Yu, Chairman of China Hepatitis Prevention and Control Foundation, introduced the achievements, challenges and exploration of eliminating viral hepatitis in China; Prof. Wei Lai from Beijing Tsinghua Changgung Hospital explained the "Management Process of In-Hospital Screening for Viral Hepatitis C in China" and shared implementation cases; Prof. Zhang Wenhong, Director of Infection Department of Shanghai Huashan Hospital, introduced the ideas and initiatives of eliminating viral hepatitis under the new epidemic; Mr. Li Mingyang, Director of China Liver Health, introduced the organization's recent efforts to promote the integration of medicine and prevention, academic exchanges on liver disease and public welfare activities. Professor Xu Xiaoyuan, Chairman of the Chinese Medical Association's Hepatology Section, presided over the launch of the "Ganlin Programme " for early screening of people at high risk of liver cancer. Launch of the "Grain Programme " for early screening of high-risk groups Promoting early diagnosis and treatment of liver cancer The "Ganlin Programme" for the early screening of high-risk groups of liver cancer was jointly launched by the Liver Fibrosis/Cirrhosis/Portal Hypertension Group of the Hepatology Branch of the Chinese Medical Association, the Hepatology Group of the Hepatology Branch of the Chinese Medical Association, and the China Liver Health , supported by Herui Gene, the Chinese Journal of Liver Diseases, the Chinese Journal of Clinical Infectious Diseases, and the Chinese Journal of Health Management. Through the cfdna whole genome sequencing liver cancer early screening technology recommended by the expert consensus on China's liver cancer early screening strategy, the screening of high-risk groups such as chronic hepatitis B, hepatitis C and liver cirrhosis will be carried out nationwide in the form of "academic training + community education + hospital screening", so as to promote early warning and diagnosis of liver cancer and reduce the mortality rate of liver cancer in China.  Professor Xu Xiaoyuan leads the launch of the "Ganlin Programme " for early screening of people at high risk of liver cancer Zhuang Hui, Wei Lai, Hou Jinlin, Duan Zhongping, Nan Yuemin, Ren Hong, Zhang Wenhong, Tang Hong, Dou Xiaoguang, Xie Qing, Hu Peng, Zhang Ling Yi, Li Mingyang, Zhou Jun and other experts and industry professionals launched the Programme .  HeRuiGene CEO David Zhou and other experts in the industry attend the launch ceremony The number of new cases of liver cancer in China accounts for 55% of the world, and the number of patients is the highest in the world. Due to the insidious onset of liver cancer, the short course of the disease and the lack of obvious early symptoms, patients usually seek treatment only when they have clinical symptoms, but the tumour has already entered the middle and late stages, losing the opportunity for surgery, and the prognosis is poor, with an overall 5-year survival rate of less than 20%. The national strategy for early diagnosis and treatment of cancer has been incorporated into the "Health China 2030" planning framework. Implementing the National Programme of Work for Action to Eliminate Hepatitis C Sharing the Hepatitis C Elimination Grassroots Strategy Model In the academic session on hepatitis C prevention and treatment, experts shared strategies, experiences, models and cases on the implementation of the "Work Plan for Action to Eliminate the Public Health Hazards of Hepatitis C (2021-2030)" jointly released by the National Health and Welfare Commission and nine other ministries and commissions. Professor Wei Lai from Beijing Tsinghua Changgung Hospital firstly explained the "Management Process of In-Hospital Screening for Viral Hepatitis C in China", shared case studies from medical institutions and invited experts in the field of liver disease and infectious disease to join the Hepatitis C Elimination Programme to work together for a "future without hepatitis C". Professor Rao Huiying of Beijing People's Hospital analyses the difficult and hot issues in the current stage of eliminating hepatitis C.  Professor Wei Lai explains the process of managing in-hospital screening for viral hepatitis C in China There are about 10 million cases of chronic hepatitis C virus (HCV) infection in China, and over 70% of those infected are undetected, which can lead to subsequent diseases such as liver cirrhosis and liver cancer, placing a heavy burden on the population's health and the national economy, health and health insurance systems. In September 2021, the National Health and Welfare Commission and nine other ministries and commissions jointly released the Work Plan for Action to Eliminate the Public Health Hazards of Hepatitis C (2021- 2030)" requires comprehensive implementation of hepatitis C prevention and control measures and safeguards, and clearly sets out the work assessment targets for 2021, 2025 and 2030. Dong Hongjun, deputy director of Ningbo CDC, introduced the government led "four in one" working mechanism to eliminate hepatitis C; Li Mingyang, director of the China United Liver Health Promotion Center, introduced the case of eliminating hepatitis C by taking social organizations as the leading role in realizing the county level linkage between medicine and prevention; Wu Chao, vice president of Nanjing Drum Tower Hospital, introduced the operation experience of promoting hepatitis C screening, testing and treatment in the tertiary A hospital; Li Lan, Vice President of the Ji tian Center Hospital in Tianfu New Area, Sichuan Province, introduced the successful case of eliminating hepatitis C in the neighborhood through the community family doctor signing model; Wu Biao, a doctor in the Department of Infection of Hainan People's Hospital, introduced the experience of eliminating hepatitis C focusing on special drug users; Zhou Desheng, chairman of Beijing Kaiyin Technology, introduced the practice of eliminating hepatitis C under the Internet medical model.
Li Mingyang, Director, China Liver Health Introducing the progress of the China Hepatitis C Elimination Programme  Li Lan, Deputy Director, Ji Tian Central Health Centre, Tianfu New Area, Sichuan Presenting a community-wide case for hepatitis C elimination  Ji Tian Central Health Centre in Xi'an Community Resident health education to promote public health screening for hepatitis C Li Mingyang, Director of the China Liver Health , introduces the progress of the China Hepatitis C Elimination Public Welfare Programme .In September 2017, under the guidance of the National Bureau of Disease Control and Prevention and the China Center for Disease Control and Prevention, the China Union Liver Health Promotion Center jointly launched the Programme to carry out training for grassroots health care workers, public science education, screening and diagnosis for high-risk groups, treatment follow-up and special hardship support for patients, research on the mechanism system and interactive policy innovation. By November 2021 As of November 2021, 156 training sessions have been organized under the Hepatitis C Elimination Programme , with more than 8,000 health care workers trained on site, more than 100,000 participants online, more than 120,000 people screened and tested for hepatitis C free of charge, and more than 7,000 people found to be antibody- positive and promoted follow-up diagnosis and treatment.  China Hepatitis C Eradication Programme held "Collaboration - Hepatitis C Free Hospital" Hospital-wide training sessions to help Qingdao University Hospital and other institutions Implementing in-hospital hepatitis C screening management Building on the national demonstration Programme "Liver Health Promotion" Supporting grassroots immunisation against hepatitis B Professor Cui Fuqiang from Peking University Health Science Center introduced the work of the "Liver Health Promotion Programme " supported by the central government to support the prevention and control of hepatitis B in grassroots CDCs nationwide. Hepatitis B is the category B infectious disease with the highest number of reported cases of legally reported infectious diseases in China. It is estimated that there are about 86 million hepatitis B virus carriers nationwide, of which about 28 million are slow hepatitis B patients who need treatment. Continued strengthening of hepatitis B vaccination and cutting off the transmission route at source is the basis for the campaign to eliminate hepatitis B.  Mudan District, Heze City, Shandong Province, launched a public service campaign on "Liver Health Promotion Demonstration Zone" Since 2020, with the support of the China Liver Health and North China Pharmaceutical's Jintan Biological Charity, more than RMB 3 million has been invested in hepatitis B prevention and control materials and training, supporting grassroots CDCs in 15 provinces, including Shandong, Henan, Sichuan, Annex, Guizhou, Hunan and Jilin, to create 42 "Liver Health Demonstration Areas". The Programme is based on doing practical work for the grassroots, with the goal of protecting the public from the threat of hepatitis B. Focusing on "moving the gates of prevention forward", 233 training sessions on hepatitis B prevention and control techniques were conducted for public health staff of the CDC, covering nearly 10,000 people, 329 campus and township publicity activities were conducted, covering 1,864,000 people, and 1,459,000 people participated in voluntary public interest testing. 1,459,000 people, and completed 527,000 active preventive vaccinations, which were warmly applauded by the relevant regional CDC departments and the public. In July 2021, the relevant achievements were included in the "Exhibition of Party Building Achievements of Ministry-controlled Social Organizations" by the Ministry of Civil Affairs of the People's Republic of China.  "The Liver Health Promotion Programme" was awarded by the Ministry of Civil Affairs of the People's Republic of China Included in the "Exhibition on the achievements of party building in social organizations under the control of the Ministry" The "China Liver Health Promotion Forum" is one of the sub-forums of the 20th National Conference on Viral Hepatitis and Liver Diseases of the Chinese Medical Association and the Annual Meeting Week of the Chinese Medical Association Infectious Diseases Section and the Chinese Medical Association Hepatology Section in 2021. Chinese scholars and experts in the field of liver disease and infectious diseases, representatives of primary health care institutions and heads of relevant institutions Jia Jidong, Hou Jinlin, Tang Hong, Duan Zhongping, Xu Jie, Xu Xiaoyuan, Liu Xueen, Yang Ming, Luo Gang, Liu Yali, Chen Xing, Wei Lai, Nan Yuemin, Feng Bo, Li Jie, Rong Yihui, Lu Haiying, Lu Yong, Xu Xiaoyuan, Huang Yuan and Shen Yingsheng chaired relevant sessions of the forum. |
关注官方微信 
